Management of Patients With Peripheral Artery Disease
(Compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations)

A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

Developed in Collaboration With the Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine, and Society for Vascular Surgery

ACCF/AHA Task Force Members

Jeffrey L. Anderson, MD, FACC, FAHA, Chair
Jonathan L. Halperin, MD, FACC, FAHA, Chair-Elect
Nancy Albert, PHiD, CCNS, CCRN
Biykem Bozkurt, MD, PHiD, FACC, FAHA
Ralph G. Brindis, MD, MPH, MACC
Lesley H. Curtis, PHiD

David DeMets, PHiD
Robert A. Guyton, MD, FACC
Judith S. Hochman, MD, FACC, FAHA
Richard J. Kovacs, MD, FACC, FAHA
E. Magnus Ohman, MD, FACC
Susan J. Pressler, PHiD, RN, FAAN, FAHA
Frank W. Sellke, MD, FACC, FAHA
Win-Kuang Shen, MD, FACC, FAHA

2011 Writing Group Members

Thom W. Rooke, MD, FACC, Chair†
Alan T. Hirsch, MD, FACC, Vice Chair*Sanjay Misra, MD, FAHA, FSIR,
Vice Chair‡Anton N. Sidawy, MD, MPH, FACS,
Vice Chair§Joshua A. Beckman, MD, FACC, FAHA∥
Laura Findeiss, MD‡Jafar Golzarian, MD†Heather L. Gornik, MD, FACC, FAHA‡Jonathan L. Halperin, MD, FACC, FAHA¶Michael R. Jaff, DO, FACC**Gregory L. Moneta, MD, FACS†

Jeffrey W. Olin, DO, FACC, FAHA*#
James C. Stanley, MD, FACS†Christopher J. White, MD, FACC, FAHA,
FSCAI***John V. White, MD, FACS†R. Eugene Zierler, MD, FACS†

*Writing group members are required to recuse themselves from voting on sections where their specific relationships with industry and other entities may apply; see Appendix 1 for recusal information. †ACCF/AHA Representative, ‡Society of Interventional Radiology Representative, §Society for Vascular Medicine Representative, ¶ACCF/AHA Task Force on Practice Guidelines Liaison, #ACCF/AHA Task Force on Performance Measures Liaison, and **Society for Cardiovascular Angiography and Interventions Representative.

This document was approved by the American College of Cardiology Foundation Board of Trustees and the American Heart Association Science Advisory and Coordinating Committee in July 2011.


This article is copublished in Circulation.

Copies: This document is available on the World Wide Web sites of the American College of Cardiology (http://www.cardiosource.org) and the American Heart Association (my.americanheart.org). For copies of this document, please contact Elsevier Inc. Reprint Department, fax (212) 633-3820, e-mail reprints@elsevier.com.

Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American College of Cardiology Foundation. Please contact Elsevier’s permission department at healthpermissions@elsevier.com.
2005 Writing Committee Members

Alan T. Hirsch, MD, FACC, Chair
Ziv J. Haskal, MD, FAHA, FSIR, Co-Chair
Norman R. Hertzer, MD, FACS, Co-Chair
Curtis W. Bakal, MD, MPH, FAHA
Mark A. Creager, MD, FACC, FAHA
Jonathan L. Halperin, MD, FACC, FAHA
Loren F. Hiratzka, MD, FACC, FAHA, FASCI
William R.C. Murphy, MD, FACC, FACS
Jeffrey W. Olin, DO, FACC
Jules B. Puschett, MD, FAHA
Kenneth A. Rosenfeld, MD, FACC
David Sacks, MD, FSIR
James C. Stanley, MD, FACS
Lloyd M. Taylor, Jr, MD, FACS
Christopher J. White, MD, FACC, FAHA, FSCAI
John V. White, MD, FACS
Rodney A. White, MD, FACS

TABLE OF CONTENTS

Introduction .............................................................................................................

1. Vascular History and Physical Examination: Recommendations .....................

2. Lower Extremity PAD: Recommendations ........................................................

2.1. Clinical Presentation ......................................................................................

2.1.1. Asymptomatic .........................................................................................

2.1.2. Claudication ............................................................................................

2.1.3. Critical Limb Ischemia ..........................................................................

2.1.4. Acute Limb Ischemia ............................................................................

2.1.5. Prior Limb Arterial Revascularization ....................................................

2.2. Diagnostic Methods ....................................................................................

2.2.1. Ankle- and Toe-Brachial Indices, Segmental Pressure Examination .............

2.2.2. Pulse Volume Recording ........................................................................

2.2.3. Continuous-Wave Doppler Ultrasound ...................................................

2.2.4. Treadmill Exercise Testing With and Without ABI Assessments and 6-Minute Walk Test...

2.2.5. Duplex Ultrasound ............................................................................... 

2.2.6. Computed Tomographic Angiography ...................................................

2.2.7. Magnetic Resonance Angiography .........................................................

2.2.8. Contrast Angiography ...........................................................................

2.3. Treatment ....................................................................................................

2.3.1. Cardiovascular Risk Reduction ............................................................... 

2.3.1.1. Lipid-Lowering Drugs .....................................................................

2.3.1.2. Antihypertensive Drugs ..................................................................

2.3.1.3. Diabetes Therapies ...........................................................................

2.3.1.4. Smoking Cessation ...........................................................................

2.3.1.5. Homocysteine-Lowering Drugs .........................................................

2.3.1.6. Antiplatelet and Antithrombotic Drugs ..............................................

2.3.2. Claudication ...........................................................................................

2.3.2.1. Exercise and Lower Extremity PAD Rehabilitation ..............................

2.3.2.2. Medical and Pharmacological Treatment for Claudication .................

2.3.2.2.1. Clostazol .....................................................................................

2.3.2.2.2. Pentoxyfylline .......................................................................... 

2.3.2.2.3. Other Proposed Medical Therapies ..............................................

2.3.2.3. Endovascular Treatment for Claudication ........................................

2.3.2.4. Surgery for Claudication ..................................................................

2.3.2.4.1. Indications ...................................................................................

2.3.3. CLI and Treatment for Limb Salvage .....................................................

2.3.3.1. Medical and Pharmacological Treatment for CLI ............................

2.3.3.1.1. Prostaglandins .........................................................................

2.3.3.1.2. Angiogenic Growth Factors ........................................................

2.3.3.2. Endovascular Treatments for CLI ...................................................

2.3.3.3. Thrombolysis for Acute and CLI ......................................................

2.3.3.4. Surgery for CLI ..............................................................................

2.3.3.4.1. Infoprocures: Aortoiliac Occlusive Disease ................................

2.3.3.4.2. Outflow Procedures: Infrainguinal Disease ................................

2.3.3.4.3. Postoperative Care .................................................................

2.3.3.4.3.1. Preoperative Evaluation .........................................................

2.3.3.4.3.2. Inflow Procedures: Aortoiliac Occlusive Disease ......................

2.3.3.4.3.3. Outflow Procedures: Infrainguinal Disease ............................

2.3.3.4.3.4. Follow-up After Vascular Surgical Procedures ........................

2.3.3.4.3.4.1. Preoperative Evaluation .........................................................

2.3.3.4.3.4.2. Inflow Procedures: Aortoiliac Occlusive Disease ...................

2.3.3.4.3.4.3. Outflow Procedures: Infrainguinal Disease ........................

2.3.3.4.3.4.4. Postoperative Care ...............................................................
Introduction

This document is a compilation of the current American College of Cardiology Foundation/American Heart Association (ACCF/AHA) practice guideline recommendations for peripheral artery disease from the “ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic)” and the “2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (Updating the 2005 Guideline).” Updated and new recommendations from 2011 are noted and outdated recommendations have been removed. No new evidence was reviewed, and no recommendations included here are original to this document. The ACCF/AHA Task Force on Practice Guidelines chooses to republish the recommendations in this format to provide the complete set of practice guideline recommendations in a single resource. Because this document includes recommendations only, please refer to the respective 2005 and 2011 articles for all introductory and supportive content until the entire full-text guideline is revised. In the future, the ACCF/AHA Task Force on Practice Guidelines will maintain a continuously updated full-text guideline.

1. Vascular History and Physical Examination: Recommendations

2. Lower Extremity PAD: Recommendations

2.1. Clinical Presentation

2.1.1. Asymptomatic

CLASS I
1. A history of walking impairment, claudication, ischemic rest pain, and/or nonhealing wounds is recommended as a required component of a standard review of symptoms for adults 50 years and older who have atherosclerosis risk factors and for adults 70 years and older. (Level of Evidence: C)

2. Individuals with asymptomatic lower extremity PAD should be identified by examination and/or measurement of the ankle-brachial index (ABI) so that therapeutic interventions known to diminish their increased risk of myocardial infarction (MI), stroke, and death may be offered. (Level of Evidence: B)

3. Smoking cessation, lipid lowering, and diabetes and hypertension treatment according to current national treatment guidelines are recommended for individuals with asymptomatic lower extremity PAD. (Level of Evidence: B)

4. Antiplatelet therapy is indicated for individuals with asymptomatic lower extremity PAD to reduce the risk of adverse cardiovascular ischemic events. (Level of Evidence: C)

CLASS IIa
1. An exercise ABI measurement can be useful to diagnose lower extremity PAD in individuals who are at risk for lower extremity PAD who have a normal ABI (0.91 to 1.30), are without classic claudication symptoms, and have no other clinical evidence of atherosclerosis. (Level of Evidence: C)

2. A toe-brachial index or pulse volume recording measurement can be useful to diagnose lower extremity PAD in individuals who are at risk for lower extremity PAD who have an ABI greater than 1.30 and no other clinical evidence of atherosclerosis. (Level of Evidence: C)
2.1.2. Claudication

CLASS I

1. Patients with symptoms of intermittent claudication should undergo a vascular physical examination, including measurement of the ABI. (Level of Evidence: B)

2. In patients with symptoms of intermittent claudication, the ABI should be measured after exercise if the resting index is normal. (Level of Evidence: B)

3. Patients with intermittent claudication should have significant functional impairment with a reasonable likelihood of symptomatic improvement and absence of other disease that would comparably limit exercise even if the claudication was improved (e.g., angina, chronic respiratory disease, or orthopedic limitations) before undergoing an evaluation for revascularization. (Level of Evidence: C)

4. Individuals with intermittent claudication who are offered the option of endovascular or surgical therapies: (a) be provided information regarding supervised claudication exercise therapy and pharmacotherapy; (b) receive comprehensive risk factor modification and antiplatelet therapy; (c) have a significant disability, either being unable to perform normal work or having serious impairment of other activities important to the patient; and (d) have lower extremity PAD lesion anatomy such that the revascularization procedure would have low risk and a high probability of initial and long-term success. (Level of Evidence: C)

2.1.3. Critical Limb Ischemia

CLASS III

1. Arterial imaging is not indicated for patients with a normal postexercise ABI. This does not apply if other atherosclerotic causes (e.g., entrapment syndromes or isolated internal iliac artery occlusive disease) are suspected. (Level of Evidence: C)

2.1.4. Acute Limb Ischemia

CLASS I

1. Patients with acute limb ischemia and a salvageable extremity should undergo an emergent evaluation that defines the anatomic level of occlusion and that leads to prompt endovascular or surgical revascularization. (Level of Evidence: B)

CLASS III

1. Patients with acute limb ischemia and a nonviable extremity should not undergo an evaluation to define vascular anatomy or efforts to attempt revascularization. (Level of Evidence: B)

2.2. Diagnostic Methods

2.2.1. Ankle- and Toe-Brachial Indices, Segmental Pressure Examination

CLASS I

1. **2011 Updated Recommendation:** The resting ABI should be used to establish the lower extremity PAD diagnosis in patients with suspected lower extremity PAD, defined as individuals with 1 or more of the following: exertional leg symptoms, nonhealing wounds, age 65 and older, or 50 years and older with a history of smoking or diabetes. (Level of Evidence: B)

2. The ABI should be measured in both legs in all new patients with PAD of any severity to confirm the diagnosis of lower extremity PAD and establish a baseline. (Level of Evidence: B)

3. The toe-brachial index should be used to establish the lower extremity PAD diagnosis in patients in whom lower extremity PAD of any severity to confirm the diagnosis of lower extremity PAD and establish a baseline. (Level of Evidence: B)

4. Systemic antibiotics should be initiated promptly in patients with CLI, skin ulcerations, and evidence of limb infection. (Level of Evidence: B)

5. Patients with CLI and skin breakdown should be referred to healthcare providers with specialized expertise in wound care. (Level of Evidence: B)

6. Patients at risk for CLI (those with diabetes, neuropathy, chronic renal failure, or infection) who develop acute limb symptoms represent potential vascular emergencies and should be assessed immediately and treated by a specialist competent in treating vascular disease. (Level of Evidence: C)

7. Patients at risk for or who have been treated for CLI should receive verbal and written instructions regarding self-surveillance for potential recurrence. (Level of Evidence: C)
PAD is clinically suspected but in whom the ABI test is not reliable due to noncompressible vessels (usually patients with long-standing diabetes or advanced age). (Level of Evidence: B)

4. Leg segmental pressure measurements are useful to establish the lower extremity PAD diagnosis when anatomic localization of lower extremity PAD is required to create a therapeutic plan. (Level of Evidence: B)

5. **2011 New Recommendation:** ABI results should be uniformly reported with noncompressible values defined as greater than 1.40, normal values 1.00 to 1.40, borderline 0.91 to 0.99, and abnormal 0.90 or less. (Level of Evidence: B)

### 2.2.2. Pulse Volume Recording

**CLASS IIa**

1. Pulse volume recordings are reasonable to establish the initial lower extremity PAD diagnosis, assess localization and severity, and follow the status of lower extremity revascularization procedures. (Level of Evidence: B)

### 2.2.3. Continuous-Wave Doppler Ultrasound

**CLASS I**

1. Continuous-wave Doppler ultrasound blood flow measurements are useful to provide an accurate assessment of lower extremity PAD location and severity, to follow lower extremity PAD progression, and to provide quantitative follow-up after revascularization procedures. (Level of Evidence: B)

### 2.2.4. Treadmill Exercise Testing With and Without ABI Assessments and 6-Minute Walk Test

**CLASS I**

1. Exercise treadmill tests are recommended to provide the most objective evidence of the magnitude of the functional limitation of claudication and to measure the response to therapy. (Level of Evidence: B)

2. A standardized exercise protocol (either fixed or graded) with a motorized treadmill should be used to ensure reproducibility of measurements of pain-free walking distance and maximal walking distance. (Level of Evidence: B)

3. Exercise treadmill tests with measurement of pre-exercise and postexercise ABI values are recommended to provide diagnostic data useful in differentiating arterial claudication from nonarterial claudication (“pseudoclaudication”). (Level of Evidence: B)

4. Exercise treadmill tests should be performed in individuals with claudication who are to undergo exercise training (lower extremity PAD rehabilitation) so as to determine functional capacity, assess nonvascular exercise limitations, and demonstrate the safety of exercise. (Level of Evidence: B)

**CLASS IIb**

1. A 6-minute walk test may be reasonable to provide an objective assessment of the functional limitation of claudication and response to therapy in elderly individuals or others not amenable to treadmill testing. (Level of Evidence: B)

### 2.2.5. Duplex Ultrasound

**CLASS I**

1. Duplex ultrasound of the extremities is useful to diagnose anatomic location and degree of stenosis of PAD. (Level of Evidence: A)

2. Duplex ultrasound is recommended for routine surveillance after femoral-popliteal or femoral-tibial-pedal bypass with a venous conduit. Minimum surveillance intervals are approximately 3, 6, and 12 months, and then yearly after graft placement. (Level of Evidence: A)

**CLASS IIa**

1. Duplex ultrasound of the extremities can be useful to select patients as candidates for endovascular intervention. (Level of Evidence: B)

2. Duplex ultrasound can be useful to select patients as candidates for surgical bypass and to select the sites of surgical anastomosis. (Level of Evidence: B)

**CLASS IIb**

1. The use of duplex ultrasound is not well established to assess long-term patency of percutaneous transluminal angioplasty. (Level of Evidence: B)

2. Duplex ultrasound may be considered for routine surveillance after femoral-popliteal bypass with a synthetic conduit. (Level of Evidence: B)

### 2.2.6. Computed Tomographic Angiography

**CLASS IIb**

1. Computed tomographic angiography (CTA) of the extremities may be considered to diagnose anatomic location and presence of significant stenosis in patients with lower extremity PAD. (Level of Evidence: B)

2. CTA of the extremities may be considered as a substitute for magnetic resonance angiography (MRA) for those patients with contraindications to MRA. (Level of Evidence: B)

### 2.2.7. Magnetic Resonance Angiography

**CLASS I**

1. MRA of the extremities is useful to diagnose anatomic location and degree of stenosis of PAD. (Level of Evidence: A)

2. MRA of the extremities should be performed with gadolinium enhancement. (Level of Evidence: B)

3. MRA of the extremities is useful in selecting patients with lower extremity PAD as candidates for endovascular intervention. (Level of Evidence: A)

**CLASS IIb**

1. MRA of the extremities may be considered to select patients with lower extremity PAD as candidates for surgical bypass and to select the sites of surgical anastomosis. (Level of Evidence: B)

2. MRA of the extremities may be considered for postrevascularization (endovascular and surgical bypass) surveillance in patients with lower extremity PAD. (Level of Evidence: B)

### 2.2.8. Contrast Angiography

**CLASS I**

1. Contrast angiography provides detailed information about arterial anatomy and is recommended for evaluation of patients with lower extremity PAD when revascularization is contemplated. (Level of Evidence: B)

2. A history of contrast reaction should be documented before the performance of contrast angiography and appropriate pretreatment administered before contrast is given. (Level of Evidence: B)

3. Decisions regarding the potential utility of invasive therapeutic interventions (percutaneous or surgical) in patients with lower extremity PAD should be made with a complete anatomic
1. Treatment with a hydroxymethyl glutaryl coenzyme-A reductase inhibitor (statin) medication is indicated for all patients with PAD to achieve a target low-density lipoprotein cholesterol level of less than 100 mg per dL. (Level of Evidence: B)

CLASS IIa
1. Treatment with a hydroxymethyl glutaryl coenzyme-A reductase inhibitor (statin) medication to achieve a target low-density lipoprotein cholesterol level of less than 70 mg per dL is reasonable for patients with lower extremity PAD at very high risk of ischemic events. (Level of Evidence: B)

2. Treatment with a fibric acid derivative can be useful for patients with PAD and low high-density lipoprotein cholesterol, normal low-density lipoprotein cholesterol, and elevated triglycerides. (Level of Evidence: C)

2.3.1.4. SMOKING CESSATION

CLASS I
1. Patients who are smokers or former smokers should be asked about status of tobacco use at every visit. (Level of Evidence: A)

CLASS IIa
1. In the absence of contraindication or other compelling clinical indication, 1 or more of the following pharmacological therapies should be offered: varenicline, bupropion, and nicotine replacement therapy. (Level of Evidence: A)
2.3.1.5. HOMOCYSTEINE-LOWERING DRUGS

**CLASS IIb**

1. The effectiveness of the therapeutic use of folic acid and B₁₂ supplements in individuals with lower extremity PAD and homocysteine levels greater than 14 micromoles per liter is not well established. (Level of Evidence: C)

2.3.1.6. ANTIPLATELET AND ANTITHROMBOTIC DRUGS

**CLASS I**

1. 2011 Updated Recommendation: Antiplatelet therapy is indicated to reduce the risk of MI, stroke, and vascular death in individuals with symptomatic atherosclerotic lower extremity PAD, including those with intermittent claudication or CLI prior lower extremity revascularization (endovascular or surgical), or prior amputation for lower extremity ischemia. (Level of Evidence: A)

2. 2011 Updated Recommendation: Aspirin, typically in daily doses of 75 to 325 mg, is recommended as safe and effective antiplatelet therapy to reduce the risk of MI, stroke, or vascular death in individuals with symptomatic atherosclerotic lower extremity PAD, including those with intermittent claudication or CLI, prior lower extremity revascularization (endovascular or surgical), or prior amputation for lower extremity ischemia. (Level of Evidence: B)

3. 2011 Updated Recommendation: Clopidogrel (75 mg per day) is recommended as a safe and effective alternative antiplatelet therapy to aspirin to reduce the risk of MI, ischemic stroke, or vascular death in individuals with symptomatic atherosclerotic lower extremity PAD, including those with intermittent claudication or CLI, prior lower extremity revascularization (endovascular or surgical), or prior amputation for lower extremity ischemia. (Level of Evidence: B)

**CLASS IIa**

1. 2011 New Recommendation: Antiplatelet therapy can be useful to reduce the risk of MI, stroke, or vascular death in asymptomatic individuals with an ABI less than or equal to 0.90. (Level of Evidence: C)

**CLASS IIb**

1. 2011 New Recommendation: The usefulness of antiplatelet therapy to reduce the risk of MI, stroke, or vascular death in asymptomatic individuals with borderline abnormal ABI, defined as 0.91 to 0.99, is not well established. (Level of Evidence: A)

2. 2011 New Recommendation: The combination of aspirin and clopidogrel may be considered to reduce the risk of cardiovascular events in patients with symptomatic atherosclerotic lower extremity PAD, including those with intermittent claudication or CLI, prior lower extremity revascularization (endovascular or surgical), or prior amputation for lower extremity ischemia and who are not at increased risk of bleeding and who are high perceived cardiovascular risk. (Level of Evidence: B)

**CLASS III: NO BENEFIT**

1. 2011 Updated Recommendation: In the absence of any other proven indication for warfarin, its addition to antiplatelet therapy to reduce the risk of adverse cardiovascular ischemic events in individuals with atherosclerotic lower extremity PAD is of no benefit and is potentially harmful due to increased risk of major bleeding. (Level of Evidence: B)

2.3.2. Claudication

2.3.2.1. EXERCISE AND LOWER EXTREMITY PAD REHABILITATION

**CLASS I**

1. A program of supervised exercise training is recommended as an initial treatment modality for patients with intermittent claudication. (Level of Evidence: A)

2. Supervised exercise training should be performed for a minimum of 30 to 45 minutes, in sessions performed at least 3 times per week for a minimum of 12 weeks. (Level of Evidence: A)

**CLASS IIb**

1. The usefulness of unsupervised exercise programs is not well established as an effective initial treatment modality for patients with intermittent claudication. (Level of Evidence: B)

2.3.2.2. MEDICAL AND PHARMACOLOGICAL TREATMENT FOR CLAUDICATION

2.3.2.2.1. CILOSTAZOL

**CLASS I**

1. Cilostazol (100 mg orally 2 times per day) is indicated as an effective therapy to improve symptoms and increase walking distance in patients with lower extremity PAD and intermittent claudication (in the absence of heart failure). (Level of Evidence: A)

2. A therapeutic trial of cilostazol should be considered in all patients with lifestyle-limiting claudication (in the absence of heart failure). (Level of Evidence: A)

2.3.2.2.2. PENTOXIFYLLINE

**CLASS IIb**

1. Pentoxifylline (400 mg 3 times per day) may be considered as second-line alternative therapy to cilostazol to improve walking distance in patients with intermittent claudication. (Level of Evidence: A)

2. The clinical effectiveness of pentoxifylline as therapy for claudication is marginal and not well established. (Level of Evidence: C)

2.3.2.2.3. OTHER PROPOSED MEDICAL THERAPIES

**CLASS IIb**

1. The effectiveness of L-arginine for patients with intermittent claudication is not well established. (Level of Evidence: B)

2. The effectiveness of propionyl-L-carnitine as a therapy to improve walking distance in patients with intermittent claudication is not well established. (Level of Evidence: B)

3. The effectiveness of ginkgo biloba to improve walking distance in patients with lower extremity PAD was deemed marginal and not well established. (Level of Evidence: B)

**CLASS III**

1. Oral vasodilator prostaglandins such as beraprost and iloprost are not effective medications to improve walking distance in patients with intermittent claudication. (Level of Evidence: A)

2. Vitamin E is not recommended as a treatment for patients with intermittent claudication. (Level of Evidence: C)

3. Chelation (e.g., ethylenediaminetetraacetic acid) is not indicated for treatment of intermittent claudication and may have harmful adverse effects. (Level of Evidence: A)

2.3.2.3. ENDOVASCULAR TREATMENT FOR CLAUDICATION

**CLASS I**

1. Endovascular procedures are indicated for individuals with a vocational or lifestyle-limiting disability due to intermittent clau-
dication when clinical features suggest a reasonable likelihood of symptomatic improvement with endovascular intervention and (a) there has been an inadequate response to exercise or pharmacological therapy and/or (b) there is a very favorable risk-benefit ratio (e.g., focal aortoiliac occlusive disease). (Level of Evidence: A)

2. Endovascular intervention is recommended as the preferred revascularization technique for TASC type A iliac and femoropopliteal arterial lesions. (Level of Evidence: B)

3. Translesional pressure gradients (with and without vasodilation) should be obtained to evaluate the significance of angiographic iliac arterial stenoses of 50% to 75% diameter before intervention. (Level of Evidence: C)

4. Provisional stent placement is indicated for use in the iliac arteries as salvage therapy for a suboptimal or failed result from balloon dilation (e.g., persistent translesional gradient, residual diameter stenosis >50%, or flow-limiting dissection). (Level of Evidence: B)

5. Stenting is effective as primary therapy for common iliac artery stenosis and occlusions. (Level of Evidence: B)

6. Stenting is effective as primary therapy in external iliac artery stenoses and occlusions. (Level of Evidence: C)

CLASS IIa
1. Stents (and other adjunctive techniques such as lasers, cutting balloons, atherectomy devices, and thermal devices) can be useful in the femoral, popliteal, and tibial arteries as salvage therapy for a suboptimal or failed result from balloon dilation (e.g., persistent translesional gradient, residual diameter stenosis >50%, or flow-limiting dissection). (Level of Evidence: C)

CLASS IIb
1. The effectiveness of stents, atherectomy, cutting balloons, thermal devices, and lasers for the treatment of femoral-popliteal arterial lesions (except to salvage a suboptimal result from balloon dilation) is not well-established. (Level of Evidence: A)

2. The effectiveness of uncoated/uncovered stents, atherectomy, cutting balloons, thermal devices, and lasers for the treatment of infrapopliteal lesions (except to salvage a suboptimal result from balloon dilation) is not well established. (Level of Evidence: C)

CLASS III
1. Endovascular intervention is not indicated if there is no significant pressure gradient across a stenosis despite flow augmentation with vasodilators. (Level of Evidence: C)

2. Primary stent placement is not recommended in the femoral, popliteal, or tibial arteries. (Level of Evidence: C)

3. Endovascular intervention is not indicated as prophylactic therapy in an asymptomatic patient with lower extremity PAD. (Level of Evidence: C)

2.3.2.4. SURGERY FOR CLAUDICATION

2.3.2.4.1. INDICATIONS

CLASS I
1. Surgical interventions are indicated for individuals with claudication symptoms who have a significant functional disability that is vocational or lifestyle limiting, who are unresponsive to exercise or pharmacotherapy, and who have a reasonable likelihood of symptomatic improvement. (Level of Evidence: B)

CLASS IIa
1. Because the presence of more aggressive atherosclerotic occlusive disease is associated with less durable results in patients younger than 50 years of age, the effectiveness of surgical intervention in this population for intermittent claudication is unclear. (Level of Evidence: B)

CLASS III
1. Surgical intervention is not indicated to prevent progression to limb-threatening ischemia in patients with intermittent claudication. (Level of Evidence: B)

2.3.2.4.2. PREOPERATIVE EVALUATION

CLASS I
1. A preoperative cardiovascular risk evaluation should be undertaken in those patients with lower extremity PAD in whom a major vascular surgical intervention is planned. (Level of Evidence: B)

2.3.2.4.3. INFLOW PROCEDURES: AORTOILIAC OCCLUSIVE DISEASE

CLASS I
1. Aortobifemoral bypass is beneficial for patients with vocational- or lifestyle-disabling symptoms and hemodynamically significant aortoiliac disease who are acceptable surgical candidates and who are unresponsive to or unsuitable for exercise, pharmacotherapy, or endovascular repair. (Level of Evidence: B)

2. Iliac endarterectomy and aortoiliac or iliofemoral bypass in the setting of acceptable aortic inflow should be used for the surgical treatment of unilateral disease or in conjunction with femoral-femoral bypass for the treatment of a patient with bilateral iliac artery occlusive disease if the patient is not a suitable candidate for aortobifemoral bypass grafting. (Level of Evidence: B)

CLASS IIa
1. Axillofemoral-femoral bypass may be considered for the surgical treatment of patients with intermittent claudication in very limited settings, such as chronic infrarenal aortic occlusion associated with symptoms of severe claudication in patients who are not candidates for aortobifemoral bypass. (Level of Evidence: B)

CLASS III
1. Axillofemoral-femoral bypass should not be used for the surgical treatment of patients with intermittent claudication except in very limited settings. (Level of Evidence: B)

2.3.2.4.4. OUTFLOW PROCEDURES: INFRAINGUINAL DISEASE

CLASS I
1. Bypasses to the popliteal artery above the knee should be constructed with autogenous vein when possible. (Level of Evidence: A)

2. Bypasses to the popliteal artery below the knee should be constructed with autogenous vein when possible. (Level of Evidence: B)

CLASS IIa
1. The use of synthetic grafts to the popliteal artery below the knee is reasonable only when no autogenous vein from ipsilateral or contralateral leg or arms is available. (Level of Evidence: A)

CLASS IIb
1. Femoral-tibial artery bypasses constructed with autogenous vein may be considered for the treatment of claudication in rare instances for certain patients. (Level of Evidence: B)
2. Because their use is associated with reduced patency rates, the effectiveness of the use of synthetic grafts to the popliteal artery above the knee is not well established. (Level of Evidence: B)

CLASS III
1. Femoral-tibial artery bypasses with synthetic graft material should not be used for the treatment of claudication. (Level of Evidence: C)

2.3.3.4. SURGERY FOR CLI

CLASS I
1. 2011 New Recommendation: For patients with limb-threatening lower extremity ischemia and an estimated life expectancy of 2 years or less in patients in whom an autogenous vein conduit is not available, balloon angioplasty is reasonable to perform whenever possible as the initial procedure to improve blood flow. (Level of Evidence: B)

2. 2011 New Recommendation: For patients with limb-threatening ischemia and an estimated life expectancy of more than 2 years, bypass surgery, when possible and when an autogenous vein conduit is available, is reasonable to perform as the initial treatment to improve blood flow. (Level of Evidence: B)

2.3.3.3. THROMBOLYSIS FOR ACUTE AND CLI

CLASS I
1. Catheter-based thrombolysis is an effective and beneficial therapy and is indicated for patients with acute limb ischemia (Rutherford categories I and IIa) of less than 14 days’ duration. (Level of Evidence: A)

CLASS IIa
1. Mechanical thrombectomy devices can be used as an adjunctive therapy for acute limb ischemia due to peripheral arterial occlusion. (Level of Evidence: B)

CLASS IIb
1. Catheter-based thrombolysis or thrombectomy may be considered for patients with acute limb ischemia (Rutherford category IIb) of more than 14 days’ duration. (Level of Evidence: B)

2.3.3.4. SURGERY FOR CLI

CLASS I
1. For individuals with combined inflow and outflow disease with CLI, inflow lesions should be addressed first. (Level of Evidence: B)

2. For individuals with combined inflow and outflow disease in whom symptoms of CLI or infection persist after inflow revascularization, an outflow revascularization procedure should be performed. (Level of Evidence: B)

3. If it is unclear whether hemodynamically significant inflow disease exists, intra-arterial pressure measurements across suprainguinal lesions should be measured before and after the administration of a vasodilator. (Level of Evidence: C)

CLASS IIa
1. 2011 New Recommendation: For patients with combined inflow and outflow disease with CLI, the presence of femoral pulses, and ABIs at rest and after exercise. (Level of Evidence: C)

2. Patients who have undergone placement of a lower extremity bypass with autogenous vein conduit should be followed up with periodic evaluations that record any return or progression of claudication symptoms; a physical examination and pulse examination of the proximal, graft, and outflow vessels; and duplex imaging of the entire length of the graft, with measurement of peak systolic velocities and calculation of velocity ratios across all lesions. (Level of Evidence: C)

3. Patients who have undergone placement of a synthetic lower extremity bypass graft should, for at least 2 years after implantation, undergo periodic evaluations that record any return or progression of claudication symptoms; a pulse examination of the proximal, graft, and outflow vessels; and assessment of ABIs at rest and after exercise. (Level of Evidence: C)

2.3.3. CLI and Treatment for Limb Salvage

2.3.3.1. MEDICAL AND PHARMACOLOGICAL TREATMENT FOR CLI

CLASS III
1. Parenteral administration of pentoxifylline is not useful for the treatment of CLI. (Level of Evidence: B)

CLASS IIb
1. Parenteral administration of PGE-1 or iloprost for 7 to 28 days may be considered to reduce ischemic pain and facilitate ulcer healing in patients with CLI, but its efficacy is likely to be limited to a small percentage of patients. (Level of Evidence: A)

CLASS III
1. Oral iloprost is not an effective therapy to reduce the risk of amputation or death in patients with CLI. (Level of Evidence: B)

2.3.3.2. ANGIogenic GROWTH FACTORS

CLASS IIb
1. The efficacy of angiogenic growth factor therapy for treatment of CLI is not well established and is best investigated in the context of a placebo-controlled trial. (Level of Evidence: C)

CLASS III
1. For individuals with combined inflow and outflow disease with CLI, inflow lesions should be addressed first. (Level of Evidence: C)

2. For individuals with combined inflow and outflow disease in whom symptoms of CLI or infection persist after inflow revascularization, an outflow revascularization procedure should be performed. (Level of Evidence: B)

3. If it is unclear whether hemodynamically significant inflow disease exists, intra-arterial pressure measurements across suprainguinal lesions should be measured before and after the administration of a vasodilator. (Level of Evidence: C)
significant, aortobiliac disease requiring intervention. (Level of Evidence: A)

2. Iliac endarterectomy, patch angioplasty, or aortiliac or iliofemoral bypass in the setting of acceptable aortic inflow should be used for the treatment of unilateral disease or in conjunction with femoral-femoral bypass for the treatment of a patient with bilateral iliac artery occlusive disease if the patient is not a suitable candidate for aortobifemoral bypass grafting. (Level of Evidence: B)

3. Axillofemoral-femoral bypass is indicated for the treatment of patients with CLI who have extensive aortiliac disease and are not candidates for other types of intervention. (Level of Evidence: B)

2.3.3.4.2. OUTFLOW PROCEDURES: INFRAINGUINAL DISEASE

CLASS I

1. Bypasses to the above-knee popliteal artery should be constructed with autogenous saphenous vein when possible. (Level of Evidence: A)

2. Bypasses to the below-knee popliteal artery should be constructed with autogenous vein when possible. (Level of Evidence: A)

3. The most distal artery with continuous flow from above and without a stenosis greater than 20% should be used as the point of origin for a distal bypass. (Level of Evidence: B)

4. The tibial or pedal artery that is capable of providing continuous and uncompromised outflow to the foot should be used as the site of distal anastomosis. (Level of Evidence: B)

5. Femoral-tibial artery bypasses should be constructed with autogenous vein, including the ipsilateral greater saphenous vein, or if unavailable, other sources of vein from the leg or arm. (Level of Evidence: B)

6. Composite sequential femoropopliteal-tibial bypass and bypass to an isolated popliteal arterial segment that has collateral outflow to the foot are both acceptable methods of revascularization and should be considered when no other form of bypass with adequate autogenous conduit is possible. (Level of Evidence: B)

7. If no autogenous vein is available, a prosthetic femoral-tibial bypass, and possibly an adjunctive procedure, such as arteriovenous fistula or vein interposition or cuff, should be used when amputation is imminent. (Level of Evidence: B)

CLASS IIa

1. Prosthetic material can be used effectively for bypasses to the below-knee popliteal artery when no autogenous vein from ipsilateral or contralateral leg or arms is available. (Level of Evidence: B)

2.3.3.4.3. POSTSURGICAL CARE

CLASS I

1. Unless contraindicated, all patients undergoing revascularization for CLI should be placed on antiplatelet therapy, and this treatment should be continued indefinitely. (Level of Evidence: A)

2. Patients who have undergone placement of aortobifemoral bypass grafts should be followed up with periodic evaluations that record any return or progression of ischemic symptoms; a physical examination, with concentration on pulse examination of the proximal, graft, and outflow vessels; and duplex imaging of the entire length of the graft, with measurement of peak systolic velocities and calculation of velocity ratios across all lesions. (Level of Evidence: A)

3. Patients who have undergone placement of a synthetic lower extremity bypass graft should undergo periodic examinations that record any return of ischemic symptoms; a pulse examination of the proximal, graft, and outflow vessels; and assessment of ABIs at rest and after exercise for at least 2 years after implantation. (Level of Evidence: A)

3. Renal Arterial Disease: Recommendations

3.1. Clinical Clues to the Diagnosis of Renal Artery Stenosis

CLASS I

1. The performance of diagnostic studies to identify clinically significant renal artery stenosis (RAS) is indicated in patients with the onset of hypertension before the age of 30 years. (Level of Evidence: B)

2. The performance of diagnostic studies to identify clinically significant RAS is indicated in patients with the onset of severe hypertension [as defined in The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC-7 report] after the age of 55 years. (Level of Evidence: B)

3. The performance of diagnostic studies to identify clinically significant RAS is indicated in patients with the following characteristics: (a) accelerated hypertension (sudden and persistent worsening of previously controlled hypertension); (b) resistant hypertension (defined as the failure to achieve goal blood pressure in patients who are adhering to full doses of an appropriate 3-drug regimen that includes a diuretic); or (c) malignant hypertension (hypertension with coexistent evidence of acute end-organ damage, i.e., acute renal failure, acutely decompensated congestive heart failure, new visual or neurological disturbance, and/or advanced [grade III to IV] retinopathy). (Level of Evidence: C)

4. The performance of diagnostic studies to identify clinically significant RAS is indicated in patients with new azotemia or worsening renal function after the administration of an ACE inhibitor or an angiotensin receptor blocking agent. (Level of Evidence: B)

5. The performance of diagnostic studies to identify clinically significant RAS is indicated in patients with sudden, unexplained pulmonary edema (especially in azotemic patients). (Level of Evidence: B)

CLASS IIa

1. The performance of diagnostic studies to identify clinically significant RAS is reasonable in patients with unexplained atrophic kidney or a discrepancy in size between the 2 kidneys of greater than 1.5 cm. (Level of Evidence: B)

6. The performance of diagnostic studies to identify clinically significant RAS is indicated in patients with sudden, unexplained renal failure, including individuals starting renal replacement therapy (dialysis or renal transplantation). (Level of Evidence: B)

CLASS IIb

1. The performance of arteriography to identify significant RAS may be reasonable in patients with multivessel coronary artery dis-
2. The performance of diagnostic studies to identify clinically significant RAS may be reasonable in patients with unexplained congestive heart failure or refractory angina. (Level of Evidence: C)

3.2. Diagnostic Methods

CLASS I
1. Duplex ultrasonography is recommended as a screening test to establish the diagnosis of RAS. (Level of Evidence: B)
2. CTA (in individuals with normal renal function) is recommended as a screening test to establish the diagnosis of RAS. (Level of Evidence: B)
3. MRA is recommended as a screening test to establish the diagnosis of RAS. (Level of Evidence: B)
4. When the clinical index of suspicion is high and the results of noninvasive tests are inconclusive, catheter angiography is recommended as a diagnostic test to establish the diagnosis of RAS. (Level of Evidence: B)

CLASS III
1. Captopril renal scintigraphy is not recommended as a screening test to establish the diagnosis of RAS. (Level of Evidence: C)
2. Selective renal vein renin measurements are not recommended as a useful screening test to establish the diagnosis of RAS. (Level of Evidence: B)
3. Plasma renin activity is not recommended as a useful screening test to establish the diagnosis of RAS. (Level of Evidence: B)
4. The captopril test (measurement of plasma renin activity after captopril administration) is not recommended as a useful screening test to establish the diagnosis of RAS. (Level of Evidence: B)

3.3. Treatment of Renovascular Disease: RAS

3.3.1. Medical Treatment

CLASS I
1. ACE inhibitors are effective medications for treatment of hypertension associated with unilateral RAS. (Level of Evidence: A)
2. Angiotensin receptor blockers are effective medications for treatment of hypertension associated with unilateral RAS. (Level of Evidence: B)
3. Calcium-channel blockers are effective medications for treatment of hypertension associated with unilateral RAS. (Level of Evidence: A)
4. Beta blockers are effective medications for treatment of hypertension associated with RAS. (Level of Evidence: A)

CLASS IIb
1. Percutaneous revascularization may be considered for treatment of an asymptomatic bilateral or solitary viable kidney with a hemodynamically significant RAS. (Level of Evidence: C)
2. The usefulness of percutaneous revascularization of an asymptomatic unilateral hemodynamically significant RAS in a viable kidney is not well established and is presently clinically unproven. (Level of Evidence: C)

3.3.2. Indications for Revascularization

3.3.2.1. ASYMPTOMATIC STENOSIS

CLASS IIb
1. Percutaneous revascularization is reasonable for patients with hemodynamically significant RAS and accelerated hypertension, resistant hypertension, malignant hypertension, hypertension with an unexplained unilateral small kidney, and hypertension with intolerance to medication. (Level of Evidence: B)

3.3.2.3. PRESERVATION OF RENAL FUNCTION

CLASS IIa
1. Percutaneous revascularization is reasonable for patients with RAS and progressive chronic kidney disease with bilateral RAS or a RAS to a solitary functioning kidney. (Level of Evidence: B)

CLASS IIb
1. Percutaneous revascularization may be considered for patients with RAS and chronic renal insufficiency with unilateral RAS. (Level of Evidence: C)

3.3.2.4. IMPACT OF RAS ON CONGESTIVE HEART FAILURE AND UNSTABLE ANGINA

CLASS I
1. Percutaneous revascularization is indicated for patients with hemodynamically significant RAS and recurrent, unexplained congestive heart failure or sudden, unexplained pulmonary edema. (Level of Evidence: B)

CLASS IIa
1. Percutaneous revascularization is reasonable for patients with hemodynamically significant RAS and unstable angina. (Level of Evidence: B)

3.3.3. Endovascular Treatment for RAS

CLASS I
1. Renal stent placement is indicated for ostial atherosclerotic RAS lesions that meet the clinical criteria for intervention. (Level of Evidence: B)
2. Balloon angioplasty with bailout stent placement if necessary is recommended for fibromuscular dysplasia lesions. (Level of Evidence: B)

3.3.4. Surgery for RAS

CLASS I
1. Vascular surgical reconstruction is indicated for patients with fibromuscular dysplastic RAS with clinical indications for interventions (same as for percutaneous transluminal angioplasty), especially those exhibiting complex disease that extends into the segmental arteries and those having macroaneurysms. (Level of Evidence: B)
2. Vascular surgical reconstruction is indicated for patients with atherosclerotic RAS and clinical indications for intervention, especially those with multiple small renal arteries or early primary branching of the main renal artery. (Level of Evidence: B)
3. Vascular surgical reconstruction is indicated for patients with atherosclerotic RAS in combination with pararenal aortic reconstructions (in treatment of aortic aneurysms or severe aortoiliac occlusive disease). (Level of Evidence: C)
4. Mesenteric Arterial Disease: Recommendations

4.1. Acute Intestinal Ischemia

4.1.1. Acute Intestinal Ischemia Caused by Arterial Obstruction

4.1.1.1. Diagnosis

Class I

1. Patients with acute abdominal pain out of proportion to physical findings and who have a history of cardiovascular disease should be suspected of having acute intestinal ischemia. (Level of Evidence: B)

2. Patients who develop acute abdominal pain after arterial interventions in which catheters traverse the visceral aorta or any proximal arteries or who have arrhythmias (such as atrial fibrillation) or recent MI should be suspected of having acute intestinal ischemia. (Level of Evidence: C)

Class III

1. In contrast to chronic intestinal ischemia, duplex sonography of the abdomen is not an appropriate diagnostic tool for suspected acute intestinal ischemia. (Level of Evidence: C)

4.1.1.2. Surgical Treatment

Class I

1. Surgical treatment of acute obstructive intestinal ischemia includes revascularization, resection of necrotic bowel, and, when appropriate, a “second look” operation 24 to 48 hours after the revascularization. (Level of Evidence: B)

4.1.1.3. Endovascular Treatment

Class IIb

1. Percutaneous interventions (including transcatheter lytic therapy, balloon angioplasty, and stenting) are appropriate in selected patients with acute intestinal ischemia caused by arterial obstructions. Patients so treated may still require laparotomy. (Level of Evidence: C)

4.1.2. Acute Nonocclusive Intestinal Ischemia

4.1.2.1. Etiology

Class I

1. Nonocclusive intestinal ischemia should be suspected in patients with low flow states or shock, especially cardiogenic shock, who develop abdominal pain. (Level of Evidence: B)

2. Nonocclusive intestinal ischemia should be suspected in patients receiving vasoconstrictor substances and medications (e.g., cocaine, ergots, vasopressin, or no repinephrine) who develop abdominal pain. (Level of Evidence: B)

3. Nonocclusive intestinal ischemia should be suspected in patients who develop abdominal pain after coarctation repair or after surgical revascularization for intestinal ischemia caused by arterial obstruction. (Level of Evidence: B)

4.1.2.2. Diagnosis

Class I

1. Arteriography is indicated in patients suspected of having nonocclusive intestinal ischemia whose condition does not improve rapidly with treatment of their underlying disease. (Level of Evidence: B)

4.1.2.3. Treatment

Class I

1. Treatment of the underlying shock state is the most important initial step in treatment of nonocclusive intestinal ischemia. (Level of Evidence: C)

2. Laparotomy and resection of nonviable bowel is indicated in patients with nonocclusive intestinal ischemia who have persistent symptoms despite treatment. (Level of Evidence: B)

Class IIa

1. Transcatheter administration of vasodilator medications into the area of vasospasm is indicated in patients with nonocclusive intestinal ischemia who do not respond to systemic supportive treatment and in patients with intestinal ischemia due to cocaine or ergot poisoning. (Level of Evidence: B)

4.2. Chronic Intestinal Ischemia

4.2.1. Diagnosis

Class I

1. Chronic intestinal ischemia should be suspected in patients with abdominal pain and weight loss without other explanation, especially those with cardiovascular disease. (Level of Evidence: B)

2. Duplex ultrasound, CTA, and gadolinium-enhanced MRA are useful initial tests for supporting the clinical diagnosis of chronic intestinal ischemia. (Level of Evidence: B)

3. Diagnostic angiography, including lateral aortography, should be obtained in patients suspected of having chronic intestinal ischemia for whom noninvasive imaging is unavailable or indeterminate. (Level of Evidence: B)

4.2.2. Endovascular Treatment for Chronic Intestinal Ischemia

Class I

1. Percutaneous endovascular treatment of intestinal arterial stenosis is indicated in patients with chronic intestinal ischemia. (Level of Evidence: B)

4.2.3. Surgical Treatment

Class I

1. Surgical treatment of chronic intestinal ischemia is indicated in patients with chronic intestinal ischemia. (Level of Evidence: B)

Class IIb

1. Revascularization of asymptomatic intestinal arterial obstructions may be considered for patients undergoing aortic/renal artery surgery for other indications. (Level of Evidence: B)

Class III

1. Surgical revascularization is not indicated for patients with asymptomatic intestinal arterial obstructions, except in patients undergoing aortic/renal artery surgery for other indications. (Level of Evidence: B)
5. Aneurysms of the Abdominal Aorta, Its Branch Vessels, and the Lower Extremities: Recommendations

5.1. Abdominal Aortic and Iliac Aneurysms

5.1.1. Etiology

5.1.1.1. Atherosclerotic Risk Factors

CLASS I
1. In patients with AAAs, blood pressure and fasting serum lipid values should be monitored and controlled as recommended for patients with atherosclerotic disease. (Level of Evidence: C)

2. Patients with aneurysms or a family history of aneurysms should be advised to stop smoking and be offered smoking cessation interventions, including behavior modification, nicotine replacement, or bupropion. (Level of Evidence: B)

5.1.2. Natural History

5.1.2.1. Aortic Aneurysm Rupture

CLASS I
1. Patients with infrarenal or juxtarenal AAAs measuring 5.5 cm or larger should undergo repair to eliminate the risk of rupture. (Level of Evidence: B)

2. Patients with infrarenal or juxtarenal AAAs measuring 4.0 to 5.4 cm in diameter should be monitored by ultrasound or computed tomographic scans every 6 to 12 months to detect expansion. (Level of Evidence: A)

CLASS IIa
1. Repair can be beneficial in patients with infrarenal or juxtarenal AAAs 5.0 to 5.4 cm in diameter. (Level of Evidence: B)

2. Repair is probably indicated in patients with suprarenal or type IV thoracoabdominal aortic aneurysms larger than 5.5 to 6.0 cm. (Level of Evidence: B)

3. In patients with AAAs smaller than 4.0 cm in diameter, monitoring by ultrasound examination every 2 to 3 years is reasonable. (Level of Evidence: B)

CLASS III
1. Intervention is not recommended for asymptomatic infrarenal or juxtarenal AAAs if they measure less than 5.0 cm in diameter in men or less than 4.5 cm in diameter in women. (Level of Evidence: A)

5.1.3. Diagnosis

5.1.3.1. Symptomatic Aortic or Iliac Aneurysms

CLASS I
1. In patients with the clinical triad of abdominal and/or back pain, a pulsatile abdominal mass, and hypotension, immediate surgical evaluation is indicated. (Level of Evidence: B)

2. In patients with symptomatic aortic aneurysms, repair is indicated regardless of diameter. (Level of Evidence: C)

5.1.3.2. Screening High-Risk Populations

CLASS I
1. Men 60 years of age or older who are either the siblings or offspring of patients with AAAs should undergo physical examination and ultrasound screening for detection of aortic aneurysms. (Level of Evidence: B)

CLASS IIa
1. Men who are 65 to 75 years of age who have ever smoked should undergo a physical examination and 1-time ultrasound screening for detection of AAAs. (Level of Evidence: B)

5.1.4. Observational Management

5.1.4.1. Blood Pressure Control and Beta-Blockade

CLASS I
1. Perioperative administration of beta-adrenergic blocking agents, in the absence of contraindications, is indicated to reduce the risk of adverse cardiac events and mortality in patients with coronary artery disease undergoing surgical repair of atherosclerotic aortic aneurysms. (Level of Evidence: A)

CLASS IIb
1. Beta-adrenergic blocking agents may be considered to reduce the rate of aneurysm expansion in patients with aortic aneurysms. (Level of Evidence: B)

5.1.5. Prevention of Aortic Aneurysm Rupture

5.1.5.1. Management Overview

CLASS I
1. 2011 Updated Recommendation: Open or endovascular repair of infrarenal AAAs and/or common iliac aneurysms is indicated in patients who are good surgical candidates. (Level of Evidence: A)

2. 2011 Updated Recommendation: Periodic long-term surveillance imaging should be performed to monitor for an endoleak, to document shrinkage or stability of the excluded aneurysm sac, and to determine the need for further intervention in patients who have undergone endovascular repair of infrarenal aortic and/or iliac aneurysms. (Level of Evidence: A)

CLASS IIa
1. 2011 New Recommendation: Open aneurysm repair is reasonable to perform in patients who are good surgical candidates but who cannot comply with the periodic long-term surveillance required after endovascular repair. (Level of Evidence: C)

CLASS IIb
1. 2011 New Recommendation: Endovascular repair of infrarenal aortic aneurysms in patients who are at high surgical or anesthetic risk as determined by the presence of coexisting severe cardiac, pulmonary, and/or renal disease is of uncertain effectiveness. (Level of Evidence: C)

5.2. Visceral Artery Aneurysms

CLASS I
1. Open repair or catheter-based intervention is indicated for visceral aneurysms measuring 2.0 cm in diameter or larger in women of childbearing age who are not pregnant and in patients of either gender undergoing liver transplantation. (Level of Evidence: B)

CLASS IIa
1. Open repair or catheter-based intervention is probably indicated for visceral aneurysms 2.0 cm in diameter or larger in women beyond childbearing age and in men. (Level of Evidence: B)

5.3. Lower Extremity Aneurysms

5.3.1. Natural History

CLASS I
1. In patients with femoral or popliteal aneurysms, ultrasound (or computed tomography or magnetic resonance) imaging is rec-
ommended to exclude contralateral femoral or popliteal aneu-
rysms and AAA. (Level of Evidence: B)

5.3.2. Management

CLASS I
1. Patients with a palpable popliteal mass should undergo an ultraso-

ond examination to exclude popliteal aneurysm. (Level of Ev-

idence: B)

2. Patients with popliteal aneurysms 2.0 cm in diameter or larger should undergo repair to reduce the risk of thromboembolic complications and limb loss. (Level of Evidence: B)

3. Patients with anastomotic pseudoaneurysms or symptomatic femoral artery aneurysms should undergo repair. (Level of Evidence: A)

CLASS IIa
1. Surveillance by annual ultrasound imaging is suggested for patients with asymptomatic femoral artery true aneurysms smaller than 3.0 cm in diameter. (Level of Evidence: C)

2. In patients with acute ischemia and popliteal artery aneurysms and absent runoff, catheter-directed thrombolysis or mechanical thrombectomy (or both) is suggested to restore distal runoff and resolve emboli. (Level of Evidence: B)

APPENDIX 1. AUTHOR RELATIONSHIPS WITH INDUSTRY (RELEVANT)—2005 ACC/AHA WRITING COMMITTEE TO DEVELOP GUIDELINES ON PERIPHERAL ARTERIAL DISEASE

<table>
<thead>
<tr>
<th>Committee Member</th>
<th>Research Grant</th>
<th>Speakers Bureau/ Honoraria</th>
<th>Stock Ownership</th>
<th>Consultant</th>
<th>Advisory Board</th>
</tr>
</thead>
<tbody>
<tr>
<td>Curtis W. Bakal</td>
<td>None</td>
<td>None</td>
<td>Northport Domain</td>
<td>None</td>
<td>Abbott Labs</td>
</tr>
<tr>
<td>Mark A. Creager</td>
<td>Eli Lilly</td>
<td>Bristol-Myers Squibb/Sanofi</td>
<td>Northport Domain</td>
<td>None</td>
<td>Bristol-Myers Squibb/Sanofi</td>
</tr>
<tr>
<td></td>
<td>Otsuka Pharmaceuticals</td>
<td>Otsuka Pharmaceuticals</td>
<td></td>
<td></td>
<td>Genvec</td>
</tr>
<tr>
<td></td>
<td>Pfizer</td>
<td></td>
<td></td>
<td></td>
<td>Geosome</td>
</tr>
<tr>
<td></td>
<td>Vasogen</td>
<td></td>
<td></td>
<td></td>
<td>Northport Domain</td>
</tr>
<tr>
<td>Jonathan L. Halperin</td>
<td>None</td>
<td>AstraZeneca Bristol-Myers Squibb/Sanofi</td>
<td>None</td>
<td>AstraZeneca Bayer AG Boehringer Ingelheim Bristol-Myers Squibb/Sanofi</td>
<td></td>
</tr>
<tr>
<td>Ziv J. Haskal</td>
<td>Bard/Impra</td>
<td>TransVascular W.L. Gore</td>
<td>None</td>
<td>Bard/Impra Endosurgery Ethicon Omnisonics TransVascular</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Boston Scientific</td>
<td>Cook</td>
<td></td>
<td></td>
<td>TransVascular</td>
</tr>
<tr>
<td></td>
<td>Cordis</td>
<td></td>
<td></td>
<td></td>
<td>TransVascular</td>
</tr>
<tr>
<td></td>
<td>Endovascular</td>
<td></td>
<td></td>
<td></td>
<td>TransVascular</td>
</tr>
<tr>
<td></td>
<td>Genetech</td>
<td></td>
<td></td>
<td></td>
<td>TransVascular</td>
</tr>
<tr>
<td></td>
<td>IntraTherapeutics</td>
<td>W.L. Gore</td>
<td></td>
<td></td>
<td>TransVascular</td>
</tr>
<tr>
<td>Norman R. Hertzer</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Loren F. Hiratzka</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

3. In patients with asymptomatic enlargement of the popliteal arteries twice the normal diameter for age and gender, annual ultrasound monitoring is reasonable. (Level of Evidence: C)

4. In patients with femoral or popliteal artery aneurysms, administration of antiplatelet medication may be beneficial. (Level of Evidence: C)

5.3.2.1. CATHETER-RELATED FEMORAL ARTERY PSEUDOANEURYSMS

CLASS I
1. Patients with suspected femoral pseudoaneurysms should be evaluated by duplex ultrasonography. (Level of Evidence: B)

2. Initial treatment with ultrasound-guided compression or thrombin injection is recommended in patients with large and/or symptomatic femoral artery pseudoaneurysms. (Level of Evidence: B)

CLASS IIa
1. Surgical repair is reasonable in patients with femoral artery pseudoaneurysms 2.0 cm in diameter or larger that persist or recur after ultrasound-guided compression or thrombin injection. (Level of Evidence: B)

2. Reevaluation by ultrasound 1 month after the original injury can be useful in patients with asymptomatic femoral artery pseudoaneurysms smaller than 2.0 cm in diameter. (Level of Evidence: B)
### Committee Member

<table>
<thead>
<tr>
<th>Committee Member</th>
<th>Research Grant</th>
<th>Speakers Bureau/Honoraria</th>
<th>Stock Ownership</th>
<th>Consultant</th>
<th>Advisory Board</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alan T. Hirsch</td>
<td>• Alteon</td>
<td>• AstraZeneca</td>
<td>None</td>
<td>• Sonosite</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>• AstraZeneca</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Bristol-Myers</td>
<td>• Bristol-Myers</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Bristol-Myers Squibb/Sanofi</td>
<td>• Sanofi</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Bristol-Myers Squibb/Sanofi Aventis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Kos Pharmaceuticals</td>
<td>• Otsuka America</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Otsuka America Pharmaceuticals</td>
<td>• Pfizer</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| William R. C. Murphy      | None                                    | None                      | None            | None       | None           |

| Jeffrey W. Olin           | • Bristol-Myers                         | None                      | None            | • Aventia  | • Abbott       |
|                           | • Bristol-Myers Squibb/Sanofi            |                           |                 |            |                |
|                           | • Bristol-Myers Squibb/Sanofi Partnership|                           |                 |            |                |
|                           | • Vasogen                               |                           |                 |            |                |

| Jules B. Puschett         | None                                    | None                      | None            | None       | None           |

| Kenneth A. Rosenfield     | • Abbott                                | • Eli Lilly               | None            | • Abbott   | • Abbott       |
|                           | • Boston Scientific                    |                           |                 |            |                |
|                           | • Cordis                                |                           |                 |            |                |
|                           | • Guidant                               |                           |                 |            |                |

| David Sacks               | None                                    | None                      | None            | • Angiotech| None           |

| James C. Stanley          | None                                    | None                      | None            | None       | None           |

| Lloyd M. Taylor, Jr       | None                                    | None                      | None            | None       | None           |

| Christopher J. White      | None                                    | None                      | None            | None       | None           |

| John White                | None                                    | None                      | None            | None       | None           |

| Rodney A. White           | • AVE Bard                              | • Multiple relationships  | None            | • Several  | None           |
|                           | • Baxter                                | with commercial           |                 | biomedical  | None           |
|                           | • Cordis J&J                            | entities that arise and   |                 | companies   | None           |
|                           | • EndoLogix                             | are met as needed         |                 |            | None           |
|                           | • EndoSonic                             |                           |                 |            |                |
|                           | • Medtronic                             |                           |                 |            |                |

This table represents the relationships of committee members with industry that were disclosed at the initial writing committee meeting in November 2002 and that were updated in conjunction with all meetings and conference calls of the writing committee. It does not necessarily reflect relationships with industry at the time of publication.

### APPENDIX 2. AUTHOR RELATIONSHIPS WITH INDUSTRY AND OTHER ENTITIES (RELEVANT)—2011

ACCF/AHA FOCUSED UPDATE OF THE GUIDELINE FOR THE MANAGEMENT OF PATIENTS WITH PERIPHERAL ARTERY DISEASE

<table>
<thead>
<tr>
<th>Writing Group Member</th>
<th>Employment</th>
<th>Consultant</th>
<th>Speakers’ Bureau</th>
<th>Ownership/Partnership/Principal</th>
<th>Personal Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
<th>Voting Recusal (by section)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thom W. Rooke, Chair</td>
<td>Mayo Clinic—Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Alan T. Hirsch, Vice Chair</td>
<td>University of Minnesota Medical School: CardiOvascular Division—Vascular Medicine Program: Director; Professor of Medicine: Epidemiology and Community Health</td>
<td>• eV3</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>• Abbott Vascular</td>
<td>None</td>
<td>2.5.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Vascular BMS/sanofi-aventis</td>
<td></td>
<td>2.6.1.6</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Cytokinetics</td>
<td></td>
<td>2.6.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Sanofi-aventis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• ViroMed (PI)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sanjay Misra, Vice Chair</td>
<td>Mayo Clinic: Division of Vascular and Interventional Radiology—Associate Professor of Radiology</td>
<td>• Johnson &amp; Johnson</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>2.6.3</td>
</tr>
</tbody>
</table>
This table represents the relationships of writing group members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing group during the document development process.

The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of >5% of the voting stock or share of the business entity; or ownership of $10,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.

According to the ACCF/AHA, a person has a relevant relationship IF: (a) The relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or (b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or (c) the person or a member of the person’s household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document.

*Writing group members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply. Section numbers are from the 2011 Focused Update.

†Significant relationship.
‡No financial benefit.

DSMB indicates Data and Safety Monitoring Board; and PI, principal investigator.